Study to Assess the Efficacy, Safety and Tolerability of Laquinimod Compared to Placebo

- Primary Progressive Multiple Sclerosis
- Completed

Study Title: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo

Teva Identifier: TV5600-CNS-20006 | 2014-001579-30

ClinicalTrials.gov Identifier: NCT02284568

Study Status: Completed

Trial Condition(s): Primary Progressive Multiple Sclerosis

Interventions: Drug: Placebo | Drug: Laquinimod

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 25 Years to 55 Years

Trial Duration: January 12, 2015 - October 1, 2017

Phase: Phase 2

Study Type

Interventional